Methylxanthines as Potential Inhibitor of SARS-CoV-2: an In Silico Approach [0.03%]
基于计算机模拟的甲基黄嘌呤类化合物作为SARS-CoV-2抑制剂的研究
Rajan Rolta,Deeksha Salaria,Bhanu Sharma et al.
Rajan Rolta et al.
The aim of the present study was to test the binding affinity of methylxanthines (caffeine/theine, methylxanthine, theobromine, theophylline and xanthine) to three potential target proteins namely Spike protein (6LZG), main protease (6LU7) ...
Gopikrishna Agraharam,Agnishwar Girigoswami,Koyeli Girigoswami
Gopikrishna Agraharam
Purpose of reveiw: The root cause of many diseases like CVD, cancer, and aging is free radicals which exert their effect by interfering with different metabolic pathways. The sources of free radicals can be exogenous, lik...
Wenming Li,Juan Dou,Jing Yang et al.
Wenming Li et al.
Purpose of the review: To reason that targeting chaperone-mediated autophagy (CMA) represents a promising approach for disease therapy, we will summarize advances in researches on the relationship between CMA and diseases...
Omeed Darweesh,Ghayth M Abdulrazzaq,Radhwan N Al-Zidan et al.
Omeed Darweesh et al.
The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, or COVID-19) has been detrimental to human health, economy, and wellbeing. Little information is known on the epidemiology and outcome of the disease in a localized ...
Phytocompounds of Rheum emodi, Thymus serpyllum, and Artemisia annua Inhibit Spike Protein of SARS-CoV-2 Binding to ACE2 Receptor: In Silico Approach [0.03%]
基于金莲花、百里香和黄花的植物化合物通过计算方法抑制SARS-CoV-2刺突蛋白与ACE2受体结合
Rajan Rolta,Deeksha Salaria,PremPrakash Sharma et al.
Rajan Rolta et al.
COVID-19, the disease caused by SARS-CoV-2, has been declared as a global pandemic. Traditional medicinal plants have long history to treat viral infections. Our in silico approach suggested that unique phytocompounds such as emodin, thymol...
Kimberly Holt,Swati Nagar,Ken Korzekwa
Kimberly Holt
Purpose of review: Prior to human studies, knowledge of drug disposition in the body is useful to inform decisions on drug safety and efficacy, first in human dosing, and dosing regimen design. It is therefore of interest...
Indomethacin: Can It Counteract Bradykinin Effects in COVID-19 Patients? [0.03%]
吲哚美辛：它能对抗COVID-19患者的缓激肽作用吗？
Myasar Alkotaji,Radhwan N Al-Zidan
Myasar Alkotaji
COVID-19 represents the biggest health challenge. Although the mortality rate of COVID-19 is low, the high numbers of infected people and those with post-COVID-19 symptoms represent a real problem for the health system. A high number of pat...
The Utility of Pharmacometric Models in Clinical Pharmacology Research in Infants [0.03%]
药物动力学模型在婴幼儿临床药理学研究中的应用价值
Guohua An
Guohua An
Purpose of commentary: Acquiring knowledge on drug disposition and action in infant is challenging because of the problem of sparse and unbalanced data obtained for each individual infant due to the limited blood volume a...
Determination of Potential Drug Candidate Molecules of the Hypericum perforatum for COVID-19 Treatment [0.03%]
用于治疗COVID-19的Hypericum perforatum潜在药物候选分子的确定
Serap Yalçın,Seda Yalçınkaya,Fahriye Ercan
Serap Yalçın
The novel human coronavirus was firstly emerged in December 2019 in Wuhan, China, and has spread rapidly around the world. There is no known specific effective treatment of COVID-19. The most commonly used agents against this disease both i...
Efficacy and Safety of New and Emerging Drugs for COVID-19: Favipiravir and Dexamethasone [0.03%]
用于治疗COVID-19的新药和潜在药物的有效性和安全性：法匹拉韦和地塞米松
Shivani Sood,Gurpreet Kaur Bhatia,Prachi Seth et al.
Shivani Sood et al.
Purpose of review: The widespread respiratory disease of virus known as severe acute respiratory syndrome-coronavirus 2019 (SAR-CoV-2) had infected more than 200 countries and caused pandemic and havoc in the world. ...